177 related articles for article (PubMed ID: 8815886)
21. Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study.
Butcher SP; Fairbrother IS; Kelly JS; Arbuthnott GW
J Neurochem; 1988 Feb; 50(2):346-55. PubMed ID: 2447237
[TBL] [Abstract][Full Text] [Related]
22. Glutathione depletion and oxidative stress.
Mytilineou C; Kramer BC; Yabut JA
Parkinsonism Relat Disord; 2002 Sep; 8(6):385-7. PubMed ID: 12217624
[TBL] [Abstract][Full Text] [Related]
23. The role of de novo catecholamine synthesis in mediating methylmercury-induced vesicular dopamine release from rat pheochromocytoma (PC12) cells.
Tiernan CT; Edwin EA; Goudreau JL; Atchison WD; Lookingland KJ
Toxicol Sci; 2013 May; 133(1):125-32. PubMed ID: 23425605
[TBL] [Abstract][Full Text] [Related]
24. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease.
Chinta SJ; Andersen JK
Free Radic Biol Med; 2006 Nov; 41(9):1442-8. PubMed ID: 17023271
[TBL] [Abstract][Full Text] [Related]
25. Glutathione protects PC12 cells from ascorbate- and dopamine-induced apoptosis.
Si F; Ross GM; Shin SH
Exp Brain Res; 1998 Dec; 123(3):263-8. PubMed ID: 9860264
[TBL] [Abstract][Full Text] [Related]
26. Glutathione depletion in nigrostriatal slice cultures: GABA loss, dopamine resistance and protection by the tetrahydrobiopterin precursor sepiapterin.
Gramsbergen JB; Sandberg M; Møller Dall A; Kornblit B; Zimmer J
Brain Res; 2002 May; 935(1-2):47-58. PubMed ID: 12062472
[TBL] [Abstract][Full Text] [Related]
27. Interactions between endogenous dopamine and dopamine agonists at release modulatory receptors: multiple effects of neuronal uptake inhibitors on transmitter release.
Hoffmann IS; Talmaciu RK; Cubeddu LX
J Pharmacol Exp Ther; 1986 Aug; 238(2):437-46. PubMed ID: 2942676
[TBL] [Abstract][Full Text] [Related]
28. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
Hu XT; Wachtel SR; Galloway MP; White FJ
J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947
[TBL] [Abstract][Full Text] [Related]
29. The effect of endogenous dopamine in rotenone-induced toxicity in PC12 cells.
Dukes AA; Korwek KM; Hastings TG
Antioxid Redox Signal; 2005; 7(5-6):630-8. PubMed ID: 15890007
[TBL] [Abstract][Full Text] [Related]
30. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.
Offen D; Sherki Y; Melamed E; Fridkin M; Brenneman DE; Gozes I
Brain Res; 2000 Jan; 854(1-2):257-62. PubMed ID: 10784133
[TBL] [Abstract][Full Text] [Related]
31. Vesicular accumulation of dopamine following L-DOPA administration.
Buu NT
Biochem Pharmacol; 1989 Jun; 38(11):1787-92. PubMed ID: 2735936
[TBL] [Abstract][Full Text] [Related]
32. Spatial learning and memory deficits induced by dopamine administration with decreased glutathione.
Shukitt-Hale B; Erat SA; Joseph JA
Free Radic Biol Med; 1998 May; 24(7-8):1149-58. PubMed ID: 9626569
[TBL] [Abstract][Full Text] [Related]
33. Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum.
Ikeda K; Miura K; Himeno S; Imura N; Naganuma A
Mol Cell Biochem; 2001 Mar; 219(1-2):51-6. PubMed ID: 11354253
[TBL] [Abstract][Full Text] [Related]
34. Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration.
Toffa S; Kunikowska GM; Zeng BY; Jenner P; Marsden CD
J Neural Transm (Vienna); 1997; 104(1):67-75. PubMed ID: 9085194
[TBL] [Abstract][Full Text] [Related]
35. Altered glutathione homeostasis in animals prenatally exposed to lipopolysaccharide.
Zhu Y; Carvey PM; Ling Z
Neurochem Int; 2007 Mar; 50(4):671-80. PubMed ID: 17291629
[TBL] [Abstract][Full Text] [Related]
36. Studies on the mechanism of depletion of striatal dopamine by alpha-methyl-m-tyrosine.
Uretsky NJ; Snodgrass SR; Lorenzo AV
J Pharmacol Exp Ther; 1975 Dec; 195(3):465-79. PubMed ID: 490
[TBL] [Abstract][Full Text] [Related]
37. Role of endogenous glutathione in the oxidation of dopamine.
Rabinovic AD; Hastings TG
J Neurochem; 1998 Nov; 71(5):2071-8. PubMed ID: 9798932
[TBL] [Abstract][Full Text] [Related]
38. Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum.
Pileblad E; Magnusson T; Fornstedt B
J Neurochem; 1989 Mar; 52(3):978-80. PubMed ID: 2493072
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of 2,4-dithiobiuret on the synthesis and release of acetylcholine and dopamine from rat pheochromocytoma (PC12) cells.
Ireland LM; Yan CH; Nelson LM; Atchison WD
J Pharmacol Exp Ther; 1995 Dec; 275(3):1453-62. PubMed ID: 8531116
[TBL] [Abstract][Full Text] [Related]
40. Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. II. Release in the presence of vesicular transmitter stores.
Parker EM; Cubeddu LX
J Pharmacol Exp Ther; 1986 Apr; 237(1):193-203. PubMed ID: 3007738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
